Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, briefly discusses the importance of risk stratification in multiple myeloma. Dr Cerchione also highlights the need to redefine new prognostic scores using both cytogenetic and molecular data in order to provide patients with the best treatment approaches and combinations. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.